Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure chemotherapy in women with recurrent ovarian cancer
Recurrent Ovarian Cancer
DRUG: chemotherapy with doxorubicin and cisplatin
Clinical Benefit Rate, The clinical benefit rate comprises complete remission, partial remission, and stable disease according to RECIST criteria., 6 months
safety, left heart ejection fraction, neurological status, laparoscopy complications intraoperative, laparoscopy complications postoperative until hospital discharge, re-admission to hospital, death, 6 months
tumor apoptosis assessment, videolaparoscopy assessment of response, CA 125 assessment of response, various measures of response to therapy on the clinical, biochemical, and histological level, 6 months
This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal carcinomatosis. The primary objective of this study is to determine the Clinical Benefit Rate (CBR) according to RECIST criteria after three cycles of PIPAC with cisplatin and doxorubicin.